• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    SPI Pharma has been solving formulation challenges using superior functional materials.

    J&J, Pfizer and Roche face FDA questions over data applicability

    FIERCE PHARMA

    Stylus outlines next-gen gene editing mission with $85M in hand

    FIERCE BIOTECH

    Icotrokinra shows skin clearance in scalp and genital psoriasis

    PR NEWSWIRE

    EU Commission Approved Tremfya for Crohn`s disease in adults

    GLOBENEWSWIRE

    J&J gene therapy fails ph. 3 rare eye disease trial

    FIERCE BIOTECH

    J&J tries to reopen lawsuit against expert witness in talc cases

    FIERCE PHARMA

    J&J-backed HistoSonics explores sale at $2.5 billion valuation

    REUTERS

    US FDA approves J&J`s immune disorder drug

    PRESS RELEASE

    Johnson & Johnson at Bernstein`s 41st Annual Conference

    BUSINESSWIRE

    J&J’s TAR-200 monotherapy achieves 80% disease-free survival

    GLOBENEWSIRE

    J&J puts ImmunityBio on defense mode in bladder cancer

    FIERCE PHARMA

    Next-gen pulsed field ablation comes to the fore at HRS

    FIERCE BIOTECH

    Tremfya approved by European Commission for ulcerative colitis

    GLOBENEWSWIRE

    J&J & Lilly Concealed Breast Cancer Risks in Antipsychotics Drug

    PR NEWSWIRE

    Compremium AG Appoints Dr. Kolaleh Eskandanian to Lead Pediatrics

    ACCESSWIRE

    J&J Unveils Bladder Cancer Data at AUA, Potential Game Changer

    PR NEWSWIRE

    Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149

    GLOBENEWSWIRE

    Johnson & Johnson at 2025 RBC Capital Markets Healthcare Conf

    BUSINESSWIRE

    Johnson & Johnson CEO warns US tariffs may disrupt drug supply

    REUTERS

    Johnson & Johnson Reports Q1 2025 Results

    BUSINESSWIRE

    Johnson & Johnson Raises Quarterly Dividend by 4.8% for 63rd Year

    BUSINESSWIRE

    J&J Reports First Cases With Ottava Surgical Robot

    FIERCE BIOTECH

    Icotrokinra: 75% of adolescents with psoriasis achieve clear skin

    PR NEWSWIRE

    ValoTx Appoints Marcella Origgi as CEO

    GLOBENEWSWIRE

    EU Commission OKs DARZALEX-based Regimen for New Myeloma

    PR NEWSWIRE

    J&J Links Fcrn Blocker To Sustained Benefits As Fda Ruling Nears

    FIERCE BIOTECH

    J&J`S Shockwave To Test Javelin Lithotripsy In Coronary Arteries

    FIERCE BIOTECH

    Novo’S Wegovy, J&J’S Tremfya Led March Tv Ad Spending Totals

    FIERCE PHARMA

    Johnson & Johnson shows long-term disease control in gMG

    GLOBENEWSWIRE

    J&J showcases long-term data on nipocalimab in Myasthenia Gravis

    PR NEWSWIRE

    EU Commission OKs RYBREVANT for advanced EGFR-mutated lung cancer

    GLOBENEWSWIRE

    Johnson & Johnson at BofA Securities 2025 Healthcare Conference

    BUSINESSWIRE

    EU Commission OKs Rybrevant with Enhanze for EGFR Lung Cancer

    PR NEWSWIRE

    Tremfya reduces signs, symptoms, and damage in psoriatic arthritis

    PR NEWSWIRE

    J & J Announces Expected Closing Date for Intra-Cellular Acquisition

    BUSINESSWIRE

    US judge rejects J&J`s $10 billion baby powder settlement

    REUTERS

    Johnson & Johnson to Defeat Talc Claims in Tort System

    BUSINESSWIRE

    J&J unit ordered to pay $1.64 B in HIV drug marketing case

    REUTERS

    Tremfya® gets CHMP approval for Crohn’s Disease treatment

    GLOBENEWSWIRE

    Rybrevanta plus Lazcluze outperforms osimertinib in lung cancer

    PR NEWSWIRE

    RYBREVANT plus LAZCLUZE® demonstrates overall survival benefit

    GLOBENEWSWIRE

    Nipocalimab data at AAN 2025 show positive Phase 3 results

    PR NEWSWIRE

    J&J touts $55B in planned US investments over 4 years

    BUSINESSWIRE

    J&J`s Tremfya picks up key FDA nod in Crohn`s disease

    FIERCE PHARMA

    Rybrevant, Lazcluze Show Strong Data In 1L EGFR Lung Cancer

    PR NEWSWIRE

    Nipocalimab granted FDA Breakthrough and Fast Track designations

    PR NEWSWIRE

    J&J, Legend to invest $150M in Belgium cell therapy facility

    FIERCE PHARMA

    Lilly, J&J boosted spending on security after UnitedHealth shooting

    REUTERS

    Steqeyma, A Stelara Biosimilar, Now Available In The US

    PR NEWSWIRE

    Lilly, J&J Boosted Executive Security Spend After UNH Shooting

    REUTERS

    J&J to stop studies of depression drug due to low effectiveness

    REUTERS

    Johnson & Johnson Investor Call on First-Quarter Results

    BUSINESSWIRE

    Johnson & Johnson Names Darren Snellgrove VP, Investor Relations

    BUSINESSWIRE

    J&J’s DARZALEX Gets Positive CHMP Nod For Newly Diagnosed MM

    GLOBENEWSWIRE

    TREMFYA Gets Positive CHMP Opinion For Ulcerative Colitis

    GLOBENEWSWIRE

    J&J sues Samsung Bioepis over contract breach for Stelara

    REUTERS

    Yaqrit Strengthens Board & Management For Liver Disease Trials

    GLOBENEWSWIRE

    Intra-Cellular Therapies Reports Q4 & Full-Year 2024 Results

    GLOBENEWSWIRE

    J&J begins crucial battle over $10 billion baby powder settlement

    REUTERS

    Perceive Pharma Attracts $15M Series A Financing

    PR NEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.